Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

Hermine I. Brunner; Jonathan Akikusa; Eslam Al‐Abadi; John F. Bohnsack; Alina Boteanu; Gaëlle Chédeville; Rubén Cuttica; Wendy de la Pena; Lawrence Jung; Ozgur Kasapcopur; Katarzyna Kobusińska; Grant S. Schulert; Cláudia Lopes Santoro Neiva; Rafael Rivas‐Chacon; Juan Cruz Rizo Rodriguez; Mónica Vázquez-Del Mercado; Linda Wagner‐Weiner; Jennifer E. Weiss; Carine Wouters; Holly Posner; Ann Wouters; Cheng Chang; Claire White; Keith S. Kanik; Shixue Liu; Alberto Martini; Daniel J. Lovell; Nicolino Ruperto

doi:10.1136/ard-2023-225094

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

We report the safety, tolerability and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) in an ongoing long-term extension (LTE) study.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Brunner et al. (2024) studied this question.

synapsesocial.com/papers/68e65999b6db6435875e8b9a https://doi.org/10.1136/ard-2023-225094

View Full Paper

Ask AI

Bookmark

Share

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

Ask about this paper

Abstract

Discussion

Cite This Study

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading